Get started
Author

Johannes Cornelis van der Mijn

Observed names: J. C. Van der Mijn, J.C. Van Der Mijn, Johannes C van der Mijn, Johannes C. K. van der Mijn, Johannes C. Mijn, Johannes C. Van der Mijn, Johannes C. van der Mijn, Johannes C.K. van der Mijn, Johannes Van Der Mijn, Johannes Van der Mijn, Johannes C. van der Mijn, Van Der Mijn, J.C.
Observed institutions: Leiden University, Beth Israel Deaconess Medical Center, NewYork–Presbyterian Hospital, Harvard University, Leiden University Medical Center, Amsterdam UMC Location University of Amsterdam, The Netherlands Cancer Institute, Massachusetts General Hospital, OLVG, Amsterdam University Medical Centers, Cancer Center Amsterdam, Weill Cornell Medicine, Weill Cornell Medical Center, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam
ORCID: 0000-0001-5051-5860
Observed ORCID: 0000-0001-5051-5860
OpenAlex ID: A5058944343
Novel drugs that target the metabolic reprogramming in renal cell cancer
2016 · Johannes C. van der Mijn, David J. Panka, et al. · Cancer & Metabolism · 81
PDF
Predictive biomarkers in renal cell cancer: Insights in drug resistance mechanisms
2014 · Johannes C. van der Mijn, James W. Mier, et al. · Drug Resistance Updates · 68
Evaluation of different phospho-tyrosine antibodies for label-free phosphoproteomics
2015 · Johannes C. van der Mijn, Mariette Labots, et al. · Journal of Proteomics · 51
Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors
2025 · Femke H. Burgers, Johannes C. K. van der Mijn, et al. · Nature Reviews Nephrology · 41
Sunitinib activates Axl signaling in renal cell cancer
2016 · Johannes C. van der Mijn, Henk J. Broxterman, et al. · International Journal of Cancer · 35
PDF
Phosphotyrosine-based-phosphoproteomics scaled-down to biopsy level for analysis of individual tumor biology and treatment selection
2017 · Mariette Labots, Johannes C. van der Mijn, et al. · Journal of Proteomics · 34
Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer
2014 · Johannes C. van der Mijn, Nik Sol, et al. · Journal of Extracellular Vesicles · 34
PDF
Combined Metabolomics and Genome-Wide Transcriptomics Analyses Show Multiple HIF1α-Induced Changes in Lipid Metabolism in Early Stage Clear Cell Renal Cell Carcinoma
2019 · Johannes C. van der Mijn, Leiping Fu, et al. · Translational Oncology · 30
PDF
Transcriptional and metabolic remodeling in clear cell renal cell carcinoma caused by ATF4 activation and the integrated stress response (ISR)
2022 · Johannes C. van der Mijn, Qiuying Chen, et al. · Molecular Carcinogenesis · 28
Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
2016 · Mariette Labots, Kristy J Gotink, et al. · Experimental & Molecular Medicine · 28
PDF
Mass Spectrometry-Based Serum and Plasma Peptidome Profiling for Prediction of Treatment Outcome in Patients With Solid Malignancies
2014 · Mariette Labots, Lisette M. Schütte, et al. · The Oncologist · 23
Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series
2019 · Johannes C. van der Mijn, Bashir Al Hussein Al Awamlh, et al. · PLoS ONE · 21
PDF
NDUFA4L2 reduces mitochondrial respiration resulting in defective lysosomal trafficking in clear cell renal cell carcinoma
2023 · Jaclyn M. Kubala, Kristian B. Laursen, et al. · Cancer Biology & Therapy · 20
PDF
Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome
2020 · Mariette Labots, Thang V. Pham, et al. · Cancers · 20
PDF
Lactic Acidosis in Prostate Cancer: Consider the Warburg Effect
2017 · Johannes C. van der Mijn, Mathijs J. Kuiper, et al. · Case Reports in Oncology · 20
NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma
2020 · Ana M. Molina, Johannes C. van der Mijn, et al. · Investigational New Drugs · 19
Evaluation of potential circulating biomarkers for prediction of response to chemoradiation in patients with glioblastoma
2016 · Myra E. van Linde, Johannes C. van der Mijn, et al. · Journal of Neuro-Oncology · 18
PDF
Irinotecan-Induced Dysarthria
2012 · Albertine J. Dressel, Johannes C. van der Mijn, et al. · Case Reports in Oncology · 18
PDF
Rscreenorm: normalization of CRISPR and siRNA screen data for more reproducible hit selection
2018 · Costa Bachas, Jasmina Hodzic, et al. · BMC Bioinformatics · 16
PDF
Association of Smoking and Death from Genitourinary Malignancies: Analysis of the National Longitudinal Mortality Study
2019 · Bashir Al Hussein Al Awamlh, Jonathan E. Shoag, et al. · The Journal of Urology · 15
Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?
2023 · Elisabeth E. Fransen van de Putte, Luna van den Brink, et al. · European Urology Open Science · 14
Codon-Optimized Luciola Italica Luciferase Variants for Mammalian Gene Expression in Culture and in Vivo
2012 · Casey A. Maguire, Johannes C. van der Mijn, et al. · Molecular Imaging · 13
PDF
Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial
2026 · Jan-Jaap J. Mellema, Chantal F. Stockem, et al. · Nature Medicine · 11
The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy
2022 · Johannes C. van der Mijn, Kenneth W. Eng, et al. · Molecular Oncology · 10
PDF
Exploratory analysis from NEOAVAX, a neoadjuvant trial of avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy.
2025 · Axel Bex, Johannes Cornelis van der Mijn, et al. · Journal of Clinical Oncology · 7
PDF
Works count: 52
Citation count: 690
H-index: 18
I10-index: 24
Year
Topic
Type